March 19, 2009 - U.S. Honor Roll Hospitals Protect Patients with LifeVest INVESTOR CONTACT: A. Ernest WhitonChief Financial OfficerZOLL Medical Corporation+1 (978) 421-9655 MEDIA CONTACT: Diane EganZOLL Medical Corporation+1 (978) email@example.com U.S. HONOR ROLL HOSPITALS PROTECT PATIENTS WITH ZOLL LIFEVEST Acceptance of World’s Only Wearable Defibrillator Continues to Expand for Those at Risk of Sudden Cardiac Arrest March 19, 2009—CHELMSFORD, Mass.—ZOLL Medical Corporation (NASDAQ GS: ZOLL), a manufacturer of resuscitation devices and related software solutions, announced today that the ZOLL LifeVest® Wearable Defibrillator has been prescribed for patients by physicians at all of the “Honor Roll” hospitals designated by U.S. News and World Report. The LifeVest, the first and only wearable defibrillator, is worn by patients at increased risk for sudden cardiac arrest (SCA), allowing their physicians time to decide how best to manage them long-term, including potentially the decision to implant a cardioverter defibrillator (ICD). The LifeVest has a 98% first shock success rate for treating patients with SCA, with no bystander intervention required. The 19 “Honor Roll” hospitals include such esteemed medical facilities as Johns Hopkins in Baltimore which is ranked number one; the Mayo Clinic in Rochester, Minn.; Ronald Reagan UCLA Medical Center in Los Angeles; Cleveland Clinic in Ohio; Massachusetts General Hospital in Boston; New York Presbyterian University Hospitals of Columbia and Cornell in New York; University of California, San Francisco Medical Center; Brigham and Women’s Hospital in Boston; Duke University Medical Center, Durham, N.C.; Hospital of the University of Pennsylvania, Philadelphia; University of Washington Medical Center in Seattle; Barnes-Jewish Hospital/Washington University, St. Louis; University of Michigan Hospitals and Health Centers, Ann Arbor; University of Pittsburgh Medical Center; Vanderbilt University Medical Center, Nashville; Stanford Hospitals and Clinics, Stanford, Calif.; University of Chicago Medical Center; Cedars-Sinai Medical Center, Los Angeles; and Yale-New Haven Hospital, New Haven, Conn. To receive this designation, U. S. News analyzes data on 5,453 medical centers to produce annual specialty rankings. Only 170 hospitals were ranked in one or more specialties and, of those, just 19 were of Honor Roll caliber. “This milestone marks a significant step in the growing utilization of the LifeVest. Its use in each of the nation’s premier tertiary hospitals highlights the critical importance the LifeVest can have in improving survival rates,” said Richard A. Packer, Chairman and Chief Executive Officer of ZOLL. “The LifeVest requires no bystander intervention, offers high risk patients and their families peace of mind, and reduces a patient’s need for longer hospital stays.” The LifeVest features a unique, non-invasive technology that continuously monitors the patient’s heart. If a life-threatening heart rhythm is detected, the device alerts the patient —who may still be conscious—prior to delivering a shock. The device releases a conductive gel onto the therapy electrodes to protect the skin, and then delivers a shock to restore normal heart rhythm. The entire event, from detecting a life-threatening arrhythmia to automatically delivering a defibrillation shock, usually occurs in less than a minute. Timely defibrillation is the single most important factor in saving a SCA victim’s life. The LifeVest may be prescribed for patients following a heart attack, before or after bypass surgery or stent placement, as well as for those with cardiomyopathy or congestive heart failure that places them at particular risk. It may also be prescribed for patients whose comorbidities, including infections caused by placement of ICDs, prevent them undergoing immediate implant surgery for an ICD. To date, LifeVest has been prescribed for over 13,000 patients, and there have been almost 3,000 years of cumulative patient time wearing LifeVest. The LifeVest is specifically approved by Medicare for those at high risk of cardiac arrest. Over half of the Medicaid programs in the United States are now covering the LifeVest and more are coming online each month. Over 1,400 health plans, both commercial and state plans, now offer reimbursement for the LifeVest. About ZOLL Medical Corporation ZOLL Medical Corporation is committed to developing technologies that help advance the practice of resuscitation. With products for pacing, defibrillation, circulation, ventilation, and fluid resuscitation, ZOLL provides a comprehensive set of technologies, including Real CPR Help® and See-Thru CPR®, that help clinicians, EMS professionals, and lay rescuers resuscitate sudden cardiac arrest or trauma victims. ZOLL also designs and markets software that automates the documentation and management of both clinical and non-clinical information. ZOLL markets and sells its products in more than 140 countries. The Company has direct operations, distributor networks, and business partners throughout the U.S., Canada, Latin America, Europe, the Middle East and Africa, Asia, and Australia. During 2008 ZOLL marked the 25th anniversary of the company’s resuscitation product development. For more information, visit www.zoll.com. Certain statements contained in this press release, including statements regarding the future business of the Company, and other statements contained herein regarding matters that are not historical facts, are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled “Risk Factors” in the Company's Quarterly Report on Form 10-Q filed with the SEC on February 6, 2009. You should not place undue reliance on the forward-looking statements in this press release, and the Company disavows any obligation to update or supplement those statements in the event of any changes in the facts, circumstances, or expectations that underlie those statements. Copyright © 2009 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. ZOLL, LifeVest, Real CPR Help, and See-Thru CPR are registered trademarks of ZOLL Medical Corporation. All product names are the property of their respective owners.